The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
The REAL AF Registry is an observational, prospective, multi-center, non-randomized registry designed to obtain real-world clinical experience of Paroxysmal and Persistent ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF). Future new contact force technologies may be included as they become available in the market. Patient assessments will occur at the following time points: 1) pre-ablation, 2) procedure, 3) 10-12 weeks, 4) 6 months (monitor only) and 5) 1 year post ablation. The objective of this registry is to assess clinical outcomes, including procedural efficiency, safety, long-term, effectiveness of RF ablations in the treatment of patients with Paroxysmal or Persistent atrial fibrillation. The outcomes of the registry are: 1) long term effectiveness defined as freedom from atrial arrhythmia recurrence post 90 day blanking period, and 2) acute and late onset complications. Sites selected for this registry will already have the following pre and post procedure assessments as part of their standard of care: Patient assessments at the following time points: (1) pre-ablation or baseline, (2) procedure, (3) 10-12 weeks, (4) 6 months (monitor only) and (5) 1 year post ablation. Pre ablation/baseline assessment should include: TTE (within 6 months of procedure), CHADS2Vasc, sleep apnea, AAD status, OAC, Medical and Arrhythmia History 10-12 Week Follow-Up Office Visit: Physician evaluation, AAD status, OAC usage, repeat TTE, and Arrhythmia Reoccurrence and Treatment Assessment Monitoring: 96-hour continuous heart rhythm monitor scheduled at 6 months and 12 months post ablation, with an event monitor ordered as needed for symptomatic arrhythmias. 12 Month Follow up Office Visit: Physician evaluation, AF Type, AF Monitoring method, Sleep apnea, Post-procedure arrhythmia treatments, AF related symptoms and QOL improvement, AAD and OAC usage, CHA2DS2VASC and Arrhythmia Reoccurrence and Treatment Assessment
Study Type
OBSERVATIONAL
Enrollment
15,000
Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
University of Alabama at Birmingham
Birmingham, Alabama, United States
RECRUITINGGrandview Medical Center
Birmingham, Alabama, United States
RECRUITINGCardiology Associates of Mobile
Mobile, Alabama, United States
RECRUITINGValley Heart Rhythm Specialists
Chandler, Arizona, United States
Effectiveness at 90 days
Freedom from atrial arrhythmia recurrence at 90 days post procedure.
Time frame: 90 days
Effectiveness at 12 months
Freedom from atrial arrhythmia recurrence at 12 months post procedure.
Time frame: 12 months
Long-term Safety
Adverse events from post-procedure through the 12-month office visit date
Time frame: Post-procedure, 3 months, and 12 months
AF recurrence
Recurrence seen during monitoring with Dual/ CRT Pacer or ICD; Event Monitor; LinQ; Holter; EKG; TTE
Time frame: 12 months
Post-procedure arrhythmia treatments
Treatments for AF post-procedure
Time frame: 12 months
AF related symptoms
Presence of: weakness, fluttering, SOB, fatigue, dizziness, decrease in exercise tolerance, chest pain/pressure, heart racing/palpitations, and other (yes/no)
Time frame: 12 months
AAD Usage
Antiarrhythmic drug use (and type) post procedure and 12 months
Time frame: 12 months
OAC usage
Oral anticoagulant use at 12 months and drug type
Time frame: 12 months
CHA2DS2VASC
An estimation of stroke risk for patients with Atrial Fibrillation. Composite score of: Age (\<65= 0; 65-74=1; \>75=2) + Sex (Female=1; Male=0) + Congestive Heart Failure (Yes =1; No=0) + Hypertension (Yes= 1; No= 0) + Stroke, Transient Ischemic Attack (TIA) or thromboembolism (Yes=2; No=0) + Vascular Disease (Yes=1; No=0) + Diabetes (Yes=1; No=0). Scores range from 0 to 9, with higher scores indicating greater risk for stroke.
Time frame: 12 months
Patient reported outcome
How do you feel now compared to pre-ablation?
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arrhythmia Research Group
Jonesboro, Arkansas, United States
RECRUITINGKeck School of Medicine
Los Angeles, California, United States
RECRUITINGSanta Barbara Cottage Hospital
Santa Barbara, California, United States
TERMINATEDCommunity Memorial Hospital
Ventura, California, United States
RECRUITINGUniversity HealthCare Alliance
Walnut Creek, California, United States
COMPLETEDThe Medical Center of Aurora
Aurora, Colorado, United States
RECRUITING...and 56 more locations